If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-26. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
NASA achieved the first approach and landing test of its Space Shuttle orbiter on a Boeing 747 carrier plane on August 12, 1977, and the first orbital test flight of a complete, crewed Space Shuttle, consisting of the orbiter, an external fuel tank, and two solid rocket boosters, on April 12, 1981. The designers underestimated the time and cost of refurbishment between flights, which reduced the cost benefit of its reusability. They also overestimated its safety: two of the fleet of five orbiters were lost in fatal flight accidents: one during launch, due to failure of a solid rocket booster seal; and one on reentry, due to launch damage of a wing heat shield. The Air Force was also supposed to use the Shuttle to launch its military payloads, but shunned it in favor of its expendable launchers after the first Shuttle loss. NASA ceased production of its Apollo spacecraft and Saturn IB launcher, and used the Shuttle as its orbital workhorse until 2011, then retired it due to the safety concern. Originally, more than 150 flights over a 15-year operation were expected; actually, the Shuttles made 135 flights in the 30-year lifespan of the series. The Soviets interpreted the Shuttle as a military surveillance vehicle, and decided they had to develop their own shuttle, which they named Buran, beginning in 1974. They copied the aerodynamic design of NASA's Shuttle orbiter, which they strapped to the side of their expendable, liquid hydrogen-fueled Energia launcher.
After Independence, Pakistan vigorously pursued bilateral relations with other Muslim countries. The Ali brothers sought to project Pakistan as the natural leader of the Islamic world, partly due to its significant manpower and military strength. Khaliquzzaman, a prominent Muslim League leader, declared Pakistan's ambition to unite all Muslim countries into Islamistan, a pan-Islamic entity. These developments, alongside Pakistan's creation, didn't receive approval from the United States, with British Prime Minister Clement Attlee expressing a hope for India and Pakistan to reunite. However, due to a nationalist awakening in the Arab world at that time, there was little interest in Pakistan's Pan-Islamic aspirations. Some Arab countries perceived the 'Islamistan' project as Pakistan's bid to dominate other Muslim states. Pakistan's founder, Muhammad Ali Jinnah, consistently advocated for the Palestinian cause, shaping Pakistan's foreign policy to support Palestinian rights within the broader framework of Muslim solidarity. During the 1967 Arab-Israel war, Pakistan supported the Arab states and played a key role in securing Iran's backing for the Arab cause both within the U.N. and beyond. Pakistan's relations with Iran have been strained by sectarian tensions, with both Iran and Saudi Arabia using Pakistan as a battleground for their proxy sectarian war. Since the early days of the Iran–Iraq war, President Zia-ul-Haq played an important mediatory role, with Pakistan actively engaging in efforts to end the conflict.
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin 13 antagonist. It is given by subcutaneous injection. The most common side effects include injection site reactions, dry eye and conjunctivitis, including allergic conjunctivitis. Lebrikizumab was approved for medical use in the European Union in November 2023, in Canada in June 2024, and in the US in September 2024.
Sources: en.wikipedia.org
Internal medicine, also known as general medicine in Commonwealth nations, is a specialty for medical doctors focused on the prevention, diagnosis, and treatment of diseases in adults. Internal refers to the "treatment of diseases of the internal organs". Practitioners of internal medicine are referred to as internists in North America and physicians in Britain and most Commonwealth nations. Internists possess specialized skills in managing patients with undifferentiated or multi-system disease processes. They provide care to both hospitalized (inpatient) and ambulatory (outpatient) patients, as their patients are frequently seriously ill or require extensive medical tests. Internists often have subspecialty interests in diseases affecting particular organs or organ systems, and often contribute significantly to teaching and research. The certification process and available subspecialties may vary across different countries. Internists are qualified doctors who have undergone postgraduate training in internal medicine, and should not be confused with "interns", a term commonly used for a doctor who has obtained a medical degree but does not yet have a license to practice medicine unsupervised. There is also sometimes confusion between internal medicine and family medicine, with people mistakenly considering them equivalent. Internal medicine is also recognized as a specialty within clinical pharmacy and veterinary medicine.
== Development and current usage == Livia S. Eberlin, Ph.D., an Assistant Professor of Chemistry at the University of Texas at Austin, first reported the invention of the MasSpec Pen in 2017. Within her laboratory, the device has been used to analyze human tissue biopsies, including normal and cancerous breast, lung, ovarian, and thyroid samples. The MasSpec Pen is currently being evaluated for use on freshly excised tissue biopsies and for intraoperative use during oncology surgeries. The MasSpec Pen has been licensed to Genio Technologies, Inc., a subsidiary of MS Pen Technologies, Inc.
=== Environmental policy === Tetra Pak products have been identified as a solid waste problem by many NGOs and environmental groups. Unlike aluminum cans or glass bottles, it cannot be recycled in municipal recycling facilities. In order to stave off regulation, the company has engineered a strong Corporate Social Responsibility campaign. In 2011, Tetra Pak published a set of sustainability targets, which included maintaining its CO2 emission levels at the same level until 2020 and increasing recycling by 100 percent. Previous Tetra Pak sustainability targets (2005–2010) were met and exceeded. Maintaining current CO2 emission levels until 2020 would result in a 40 percent relative cut in emissions at an average growth rate of five percent per year, according to Food Production Daily. Tetra Pak said it will increase its use of Forest Stewardship Council (FSC) certified paper to 100 percent in 2020, with an interim target of 50 percent by 2012. The new targets will encompass the whole value chain, from suppliers to customers, putting pressure on partners to perform coherently. As of 2017, Tetra Pak was a Carbon Disclosure Project "A-lister" and 100% of its paperboard that year was either FSC-certified or came from other controlled sources that exclude "five environmentally and socially unacceptable categories as defined by the FSC." The company began producing paper straws for some of its smaller containers in 2019.
Sources: en.wikipedia.org
polyploid (of a cell or organism) Having more than two homologous copies of each chromosome; i.e. any ploidy level that is greater than diploid. Polyploidy may occur as a normal condition of chromosomes in certain cells or even entire organisms, or it may result from errors in cell division or mutations causing the duplication of the entire chromosome set.
The magnetic field in a solar active region above a sunspot can store energy that is suddenly released as a burst of motion, X-rays, and radiation when the main current sheet collapses and reconnects the field.
Short-term pair-bond: a transient mating or associations Long-term pair-bond: bonded for a significant portion of the life cycle of that pair Lifelong pair-bond: mated for life Social pair-bond: attachments for territorial or social reasons Clandestine pair-bond: quick extra-pair copulations Dynamic pair-bond: e.g. gibbon mating systems being analogous to "divorce"
=== Some UN World Food Programme grants added back === On April 8, 2025, USAID announced it was making some exceptions to the recent announcement of cancelled participation in the UN's World Food Programme. Specifically, USAID was restoring food aid to Lebanon, Syria, Somalia, Jordan, Iraq and Ecuador, and other countries for a total of 14 nations (plus the International Organization for Migration in the Pacific region). However, food aid was not restored to Yemen or Afghanistan with a State Department spokesperson saying this was “based on concern that the funding was benefiting terrorist groups, including the Houthis and the Taliban.”
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.